OSCAR ESCOBAR: Open Payments
NPI 1477670750 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$308 in 14 payments from 9 companies in 2025. Trend: 2023 $980 · 2024 $440 · 2025 $308
Food & beverage: $308
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $131 |
| ABBVIE INC. | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 1 | $30 |
| Amgen Inc. | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $17 |
| Novo Nordisk Inc | 1 | $16 |
| SHIELD THERAPEUTICS INC | 1 | $15 |
Products named: MOUNJARO, XHANCE, Repatha, GVOKE HYPOPEN, UBRELVY, TRELEGY ELLIPTA, Doc Band, Wegovy.
Industry payments across CA — which companies pay providers there.
